1. The Molecule1 / 13
The MoleculeMechanism of ActionPreclinical & Clinical EvidenceSafety ProfileIP LandscapeTeamFinancialsRegulatory PathwayMarketCompetitive LandscapeRisks & Open QuestionsOptionalityVerdictReferences

BigBio.ai Signal Report

Corbus Pharmaceuticals Holdings

NASDAQ: CRBP · Corbus Pharmaceuticals Holdings (CRBP) -- 2L oncology ADC + αvβ8 IO + peripheral CB1 obesity · 2026-05-05

CANYON-1 (CRB-913) is scheduled to read out in summer 2026 and CRB-701 at ASCO 2026; the 2L HNSCC/cervical registrational path is real, while Pliant's αvβ8 lead and zero peer-reviewed CRB-701 data leave the evidence base thin ahead of those readouts.

Cash position
$163.3M at FY2025 close (runway ~22 months mechanical, management guides 12+ months)
Lead asset (CRB-701)
Phase 1/2 NCT06265727 nectin-4 ADC; 2L HNSCC ORR 47.6% (10/21), cervical 37.5% (6/16) at ESMO 2025
Regulatory
FDA Fast Track in cervical (Dec 2024) + HNSCC (Sep 2025); randomized registrational design aligned Apr 2026
CRB-913 readout
CANYON-1 Phase 1b (NCT07310901) 12-week obesity readout summer 2026
Class precedent risk
Pliant PLN-101095 αvβ8: 18-24 month lead, AACR 2026 ORR 30%/DCR 60% in secondary-ICI-refractory
Insider activity
Net-sell C-suite + Cormorant (10% holder) -$344K Dec 2025; CMO resigning Jun 2026

1. The Molecule

1.1 History & Prior Art

  • Lenabasum (JBT-101, anabasum, ajulemic acid): First-in-class, synthetic, orally active cannabinoid-derived drug, preferentially binding CB2, nonpsychoactive. PMID 29638269 1.

"Ajulemic acid (AJA, CT-3, IP-751, JBT-101, anabasum) is a first-in-class, synthetic, orally active, cannabinoid-derived drug that preferentially binds to the CB2 receptor and is nonpsychoactive." (Burstein SH, 2018)

  • Lenabasum is also known as JBT-101, anabasum, CT-3, IP751, CPL7075. CT.gov NCT03093402 others 2; Burstein 2018 3.

1.2 Novelty Assessment

  • Lenabasum is a cannabinoid type 2 receptor (CB2) agonist with anti-inflammatory properties; described as nonimmunosuppressive. PMID 3095 4.

"Lenabasum is a nonimmunosuppressive, nonpsychoactive cannabinoid receptor type 2 (CB2) agonist that promotes resolution of innate immune responses." (2026)

  • CRB-913 is a next-generation, highly peripherally restricted CB1 inverse agonist, designed to avoid central CB1-mediated psychiatric adverse events (rimonabant precedent). 5678.
  • CRB-701 is a next-generation Nectin-4 targeting antibody-drug conjugate (ADC). 9.

2. Mechanism of Action

2.1 Target Biology

  • CB2 agonism (Lenabasum): Resolves innate immune responses, reduces proinflammatory cytokines, suppresses T-helper 1 and monocyte-derived dendritic cell cytokines. PMID 41544891 1011.
  • αvβ8 integrin (CRB-601 target): Expressed on tumor cells; binds latent TGF-β presented on immune cells, activating TGF-β to suppress anti-tumor immunity. PMID 30333313 121314.
  • CB1 inverse agonism (CRB-913): Peripheral CB1 blockade reduces appetite and improves metabolic parameters without central psychiatric effects. 1516.

2.2 Validation Layers

  • Lenabasum: Phase 2 trials in SSc, CF, DM, SLE; Phase 3 RESOLVE-1 in dcSSc not met primary endpoint but showed trends in subgroups. Preclinical models demonstrated anti-inflammatory and antifibrotic activity. Burstein 2018 17181920.
  • CRB-601: Preclinical: anti-αvβ8 antibodies inhibit tumor growth in syngeneic models, potentiate cytotoxic T-cell responses, independent of PD-1/PD-L1. PMID 30333313 212222.
  • CRB-913: DIO mouse models show weight loss, especially when combined with semaglutide; brain exposure 15x lower than monlunabant. 232425.

2.3 Target Validation Score

No single composite score is available from existing claims.

3. Preclinical & Clinical Evidence

3.1 Data Summary

Lenabasum (JBT-101) clinical program

  • Phase 2 SSc (NCT02465437): enrollment (unverified); efficacy results (unverified) 2627.
  • Phase 2 CF (NCT02465450): enrollment (unverified); efficacy results (unverified) 28.
  • Phase 2 DM (NCT02466243): enrollment (unverified); efficacy results (unverified) 29.
  • Phase 2 SLE (NCT03093402): enrollment not verified; efficacy results not available in verified evidence ledger 30-C1175.
  • Phase 3 SSc RESOLVE-1 (NCT03398837): enrollment (unverified); primary endpoint not met (detailed results not verified; no results posted per ClinicalTrials.gov) 31.
  • Phase 2 CF (NCT03451045): enrollment (unverified); pulmonary exacerbation rate for lenabasum 20 mg BID: 0.911 events/pt vs 0.842 placebo (not significant); 5 mg BID (exploratory): 0.749 vs 0.842 placebo 3233.
  • Phase 3 DM DETERMINE (NCT03813160): enrollment (unverified); results status not verified -- (unverified).

CRB-701 (Nectin-4 ADC) Phase 1/2

  • Dose escalation completed (1.8-4.5 mg/kg) 34.
  • HNSCC dose-optimization (3.6 mg/kg Q3W): ORR 47.6% (10/21), DCR 61.9% 35363738.
  • Cervical cancer: ORR 37.5% (6/16), DCR 68.8% 394041.
  • Peripheral neuropathy 8.4% (all grade 1/2), skin AEs 28.7% (grade ≥3 3/167). 4243.

CRB-913 (CB1 inverse agonist) preclinical and Phase 1

  • DIO mouse model: semaglutide induction then switch to CRB-913 produced -17.1% weight loss vs -13.6% semaglutide continuous (p<0.01) 2344.
  • Phase 1a SAD/MAD completed; favorable safety, emerging weight loss (n=12 obese MAD 150 mg, 2.9% placebo-adjusted weight loss at Day 14 per 2025-12-11 press release).
  • Phase 1b CANYON-1 initiated; CT.gov NCT07310901 estimated enrollment 252 (Part 1 PK lead-in in healthy adults plus Part 2 = 240 obese non-diabetic adults across 4 dose arms) 454647.

CRB-601 (anti-αvβ8 mAb) first patient dosed in first-in-human Phase 1/2 NCT06603844 on 2024-12-09 per Corbus press release; CT.gov trial start 2024-12-04 48.

3.2 Anti-Anchor Check

The primary endpoint failures in lenabasum Phase 3 (RESOLVE-1) were accompanied by subgroup analyses that highlighted potential benefit in patients on background mycophenolate or with early disease. Post hoc analyses and retrospective IST comparisons introduce risk of overinterpretation; use of corporate decks for competitor comparisons without head-to-head data may anchor expectations.

4. Safety Profile

4.1 FAERS Disproportionality

No verified claims in this category.

4.2 Class-Wide Signals

  • Rimonabant (CB1 inverse agonist) discontinuation study: psychiatric events main safety concern; rate ratio for psychiatric-event-related discontinuation 1.79 (95% CI 1.54-2.09) in patients with psychiatric history. PMID 23061737 4950.
  • Peripherally restricted design of CRB-913 aims to avoid these CNS adverse events; preclinical data show 15x lower brain exposure vs monlunabant 25.

4.3 Kill Shots

  • No deaths related to lenabasum in the 42-patient Phase 2 SSc trial 51; cross-trial mortality data not present in verified ledger.
  • CRB-701: Peripheral neuropathy rate 8.4% (all grade 1/2, described as best-in-class by company); eye toxicities discontinuation 4.2% 4252.
  • CRB-913 Phase 1a: favorable safety profile, no severe AEs reported 53.

5. IP Landscape

5.1 Chain of Title

No verified claims in this category.

5.2 Maintenance & Lapse Risk

No verified claims in this category.

5.3 FTO Gaps

No verified claims in this category.

6. Team

6.1 Team Background

Note: Biographical details sourced from SEC filings (T1) and company corporate deck (T3). Deck-sourced claims are company-provided and not independently verified.

  • Yuval Cohen, PhD: CEO, co-founder since 2014; previously President & co-founder of Celsus Therapeutics (2005). SEC Form 4 5455; 565758.
  • Sean Moran, CPA, MBA: CFO, co-founder since 2014; prior senior financial management in emerging biotech/medical devices. SEC Form 4 59; 606162.
  • Dominic Smethurst, M.D., M.A., M.R.C.P.: CMO since Feb 2024; former CMO of Bicycle Therapeutics. The 2026-04-07 8-K credentials him as "M.D., M.A., M.R.C.P." (the deck listed only "MA MRCP"). Resigning effective 2026-06-30. SEC 8-K 63; SEC Form 4 54; 646566.
  • Ian Hodgson, PhD: COO since 2022; previously V.P. Head of Clinical Services at TMC Pharma. SEC Form 4 67; 686970.
  • Christina Bertsch, M.A.: Head of HR. 71.

6.2 Verified Credentials

  • Yuval Cohen, PhD: PhD verified via SEC Form 4 filings 2014-2026; co-founded Celsus Therapeutics 2005 (per company deck and SEC filings). Independent academic record not separately verified.
  • Sean Moran, CPA, MBA: CPA and MBA verified via SEC Form 4 filings; prior senior financial roles in biotech/medical devices per company deck.
  • Dominic Smethurst, MA MRCP: Medical credentials verified via SEC Form 4 filings; resigning effective 2026-06-30 per 2026-04-07 8-K.
  • Ian Hodgson, PhD: PhD verified via SEC Form 4 filings; prior V.P. Head of Clinical Services at TMC Pharma per company deck.
  • Independent verification of academic degrees beyond SEC self-disclosure not performed.

6.3 Publication Record

  • Key opinion leaders: Robert Spiera (PI on SSc trials), Victoria Werth (DM), James Chmiel (CF). CT.gov overall officials. Multiple peer-reviewed publications (PMID 29638269, 29109269, 30333313, 40065521, 37098795, 41544891, etc.) with Corbus-affiliated authors.
  • CRB-701 publication gap: zero peer-reviewed publications on SYS6002 (CSPC sister molecule = CRB-701) in EuropePMC or PubMed as of 2026-05-04. Every efficacy figure in this report traces to ESMO 2025 corporate slides -- no independent peer review exists.

6.4 Flags

  • All C-suite officers sold shares in early 2026 (see Section VII). This is a routine activity but can be interpreted as modest selling.

7. Financials

7.1 Capital Raised vs. Claimed

  • Cash, cash equivalents and investments of $163M as of Dec 31, 2025. 7273.
  • Public offering proposed and priced Oct 2025; press releases confirm without disclosing amount. 747575.

7.2 Cash Runway

  • Cash bridge: $104.0M at Q3 2025 close + $70.2M net from the 2025-11-03 follow-on offering - operating burn $11M Q4 2025 ≈ $163.3M at year-end 2025-12-31, matching the FY2025 10-K disclosure.
  • ATM residual capacity ~$69.1M.
  • EisnerAmper did NOT flag substantial doubt about going concern in the FY2025 audit, despite a $555.4M accumulated deficit. Auditor silence on going-concern materially supports the company's "12 months sufficient" runway statement.

7.3 Insider Transactions

Form 4 window captured here: 2025-11-04 - 2026-05-04 only; pre-ESMO25 (2025-10-18) sales by Cohen and Smethurst are not in this snapshot.

  • CMO Dominic Smethurst sold shares in Feb-Mar 2026: 6,097 shares @ $8.2994 ($50,601.44) and 3,285 shares @ $8.0898 ($26,574.99). SEC Form 4 7677.
  • COO Ian Hodgson sold 847 shares @ $7.38 and 2,415 shares @ $8.09. SEC Form 4 7879.
  • CFO Sean Moran sold 4,701 shares @ $7.78. SEC Form 4 80.
  • CEO Yuval Cohen sold 13,871 shares @ $7.78. SEC Form 4 81.
  • Cormorant Asset Management (Bihua Chen, 10% holder): sold 30,029 shares on 2025-12-11 at $11.456 (~$343,852) -- the largest single-dollar disposition in the captured window, though only ~1.3% of Cormorant's pre-trade position. Cormorant remains a meaningful 10% holder. SEC Form 4 82.
  • Significant equity grants in Jan 2026: CEO received 50,000 shares (and 150,000 derivative), CMO 28,365 (+85,095), CFO 28,082 (+84,247), COO 28,365 (+85,095). All priced at $0 or $8.26 strike. SEC Form 4 8384858687888990.

8. Regulatory Pathway

8.1 FDA Precedent

  • FDA granted Fast Track Designation to CRB-701 for relapsed/refractory metastatic cervical cancer (Dec 2024) and head and neck squamous cell carcinoma (Sep 2025). 9192; 9394.
  • Broad alignment with FDA on registration path for CRB-701 in second-line HNSCC and cervical cancer announced Apr 2026. 9596.

8.2 Designation Status

  • CRB-701 holds two Fast Track Designations (cervical, HNSCC). No breakthrough or orphan designations verified.

8.3 Pathway Feasibility

  • CRB-701 dose optimization completed; Phase 1/2 monotherapy data readout expected mid-2026, combination with Keytruda in 1L HNSCC Q4 2026. 979899.

9. Market

9.1 Company-Estimated TAM

  • Per company deck: U.S. total incident HNSCC 2025: 73,000; locally advanced/metastatic ~50,000; 2L+ patients ~24,000. 100101102103104105.
  • Per company deck: U.S. cervical cancer: 14,000 new cases, 4,000 deaths; market $1.8B. 106107108109110111.
  • Per company deck: Source footnotes confirm reliance on public databases and analyst reports. 112.

9.2 Prevalence Data

  • HNSCC 5-year survival: localized 86%, regional 66%, distant 37%. Cervical: 88%, 70%, 39% respectively. 113114115-C3795.

9.3 Verified TAM

  • HNSCC U.S. incidence figures (73,000) cross-checked against SEER 2025 estimates: 73,790 new oral cavity and pharynx cancers, of which the squamous-cell histology accounts for the company-cited subset. Company estimate within rounding tolerance.
  • Cervical cancer U.S. incidence (14,000) consistent with ACS 2025 estimate (13,820 new cases, 4,360 deaths). Company estimate verified.
  • The $1.8B U.S. cervical cancer market figure is per the company deck citing GlobalData; we do not have independent access to that report and have not separately verified.
  • Obesity TAM (CRB-913): Wegovy 2024 net sales $8.4B, Zepbound 2024 net sales $4.93B per Novo Nordisk and Eli Lilly 10-Ks -- these set the commercial bar that any new obesity drug must clear.

9.4 SOC & Pricing

  • 1L HNSCC: Keytruda + Platinum + Paclitaxel or 5-FU; 2L: single-agent/combo chemo. 116117.
  • 1L cervical: Carbo + Paclitaxel + Beva ± Keytruda; 2L: Tivdak or single-agent chemo. 118119.
  • Pricing not verified.

10. Competitive Landscape

10.1 Competitor Stage Map

  • CRB-701 (CRB-701 = SYS6002, the CSPC sister molecule; not to be confused with SHR-A1811, which is Hengrui's HER2 topo-I ADC, an unrelated molecule) competes with PADCEV (enfortumab vedotin, Nectin-4 ADC; 1L mUC + pembro median OS 31.5 mo per Powles NEJM 2024 EV-302) in HNSCC. In HNSCC the cross-mechanism comparator is Petosemtamab (Merus EGFR×LGR5 bispecific, not an ADC; ORR 36% in HNSCC per Merus disclosures). In cervical cancer the relevant comparators are Tivdak (tisotumab vedotin) and platinum-based chemo per the company deck. PADCEV 2024 net sales $1.59B (Pfizer/Astellas filings); approved for mUC, not currently HNSCC or cervical. 120121122123124.
  • CRB-601 in αvβ8/TGF-β-axis I-O class. Class-failure precedent: bintrafusp alfa (M7824, Merck KGaA + GSK), bifunctional anti-PD-L1/TGF-β trap. GSK paid EUR 300M upfront in 2019 with up to EUR 3.7B in milestones (~$4.2B total potential); GSK returned the asset Sep 2021. Failure pattern: NSCLC INTR@PID Lung 037 halted Jan 2021 unlikely to meet PFS vs pembrolizumab; biliary tract BTC 047 reported topline ORR 10.1% Mar 2021 (below filing bar -- not a halt, ran to readout); BTC 055 halted Aug 2021. The class is unproven in oncology. Direct αvβ8 competitor with substantial clinical lead: Pliant Therapeutics PLN-101095 (oral dual αvβ8/αvβ1 inhibitor). AACR 2026 cutoff: 3 confirmed responders with median time on treatment 19 months and mean baseline target-tumor reduction 89%; secondary-ICI-refractory subset 30% ORR / 60% DCR (n=10). The Dec 2025 interim had reported 4 of 10 responses (1 CR + 3 PRs) with only 2 PRs confirmed at that cut. Phase 1b expansion enrolling. PLN-101095 has 18-24 months of clinical lead over CRB-601's first-in-human Phase 1/2 NCT06603844 (first patient dosed 2024-12-09; primary completion Nov 2026). Pliant's separate dual-αvβ6/αvβ1 IPF program (bexotegrast, BEACON-IPF) was discontinued 2025-06-27 -- an integrin-family-adjacent on-mechanism toxicity readout that any αvβ8 program should monitor.
  • CRB-913 faces monlunabant (Inversago, acquired by Novo Nordisk for $1.075B Aug 2024; CB1 inverse agonist Phase 2 for obesity) and nimacimab (Skye Bioscience BRB-101; anti-CB1 mAb whose antibody size structurally excludes the BBB, versus CRB-913's small-molecule peripheral-restriction claim that depends on empirical human CNS-exposure data). Skye's RESHAPE-1 / CBeyond Phase 2 (NCT06577090) topline expected Q3 2025 - Q1 2026 is the most consequential external de-risking event for the entire peripherally-restricted CB1 thesis. Company's own deck comparison suggests CRB-913 is superior on brain penetration, titration, and exclusion of psychiatric baseline; the comparison is internal and not independently verified. 125.
  • CRB-913 efficacy gap to incumbents. GLP-1 incumbents Wegovy (semaglutide, STEP-1 -14.9% body weight at 68 weeks per Wilding NEJM 2021) and Zepbound (tirzepatide, SURMOUNT-1 -20.9% at 72 weeks per Jastreboff NEJM 2022) set the bar. CRB-913 Phase 1a SAD/MAD reported 2.9% placebo-adjusted weight loss at Day 14 (n=12 obese MAD 150 mg). Direct comparison of the 2.9% / 14-day result against the incumbents' multi-month results is misleading -- CANYON-1 Phase 1b 12-week readout summer 2026 will be the first comparable timepoint.

10.2 Differentiator Durability

  • CRB-701 differentiators: lower free MMAE levels, longer half-life (DAR 2), ADCC/CDC functionality, potentially reduced peripheral neuropathy and skin toxicity. Competitor safety: PADCEV discontinuation 20.6% 126, BT8009 dose interruption 53% 127. 1281291301314243132126127.
  • CRB-913 differentiators: high peripheral restriction, once-daily oral, potential for maintenance after incretin therapy and monotherapy in intolerant patients. 25.

11. Risks & Open Questions

11.1 Contradicted Findings

  • Gastrointestinal event counts in NCT03451045 misrepresented 133.
  • Claim: lenabasum 20 mg group had 0.6% rhinovirus infection. Actual: 0 affected in that group, event was in placebo. Contradicted.
  • CRB-913 vehicle-switch arm rebound data omitted 134.
  • Claim: CRB-913 maintenance led to -17.1% weight loss. Actual: vehicle-switch control group rebounded to +2.1% at day 41, indicating no maintenance benefit. Contradicted.

11.2 Unsupported Claims

No verified claims in this category.

11.3 Existential vs. Manageable

  • Lead asset lenabasum failed Phase 3 in dcSSc (CRISS primary), terminated OLE; all lenabasum trials in SSc, DM, CF, SLE failed to demonstrate statistically significant primary efficacy. This removes a major value driver but may not be existential given the company's pivot to ADC and CB1 programs.
  • Safety of CB1 inverse agonists carries broad class-failure precedent: 5 historical CB1 inverse agonists have been terminated (rimonabant withdrawn, taranabant terminated 2008, surinabant, otenabant, ibipinabant). Zero approved. The company's strategy hinges on peripheral restriction and baseline psychiatric screening; if central penetration occurs in humans, psychiatric safety could scuttle the entire class approach.
  • Regulatory and clinical execution risk: CRB-701 and CRB-913 are still dose-ranging; registrational paths are not yet locked. Failure in pivotal studies would be catastrophic.
  • CRB-701 evidence quality: zero peer-reviewed publications on SYS6002/CRB-701 in EuropePMC or PubMed as of 2026-05-04. Every efficacy figure cited (ORR 47.6% HNSCC, 37.5% cervical, peripheral-neuropathy 8.4%) traces only to ESMO 2025 corporate slides. Independent peer review will materially affect risk profile. The company deck references a "CSPC Phase 3 in cervical" trial; only Phase 2 NCT06989671 in HNSCC is visible at ClinicalTrials.gov, leaving the Phase 3 cervical narrative unverifiable on the public registry.
  • CRB-601 competitive threat: Pliant Therapeutics PLN-101095 (oral dual αvβ8/αvβ1, 30% ORR / 60% DCR in secondary-ICI-refractory patients per AACR 2026) has an 18-24 month clinical lead. CRB-601's first-in-human Phase 1/2 readout is not expected until Nov 2026 -- by which point a competitor may have moved into pivotal-stage development.
  • CRB-913 CNS safety contingency: peripheral-restriction claim rests on preclinical brain:plasma ratios (15x lower than monlunabant). Human CNS exposure data have not been disclosed. The rimonabant withdrawal (EMA Oct 2008, FDA AdCom 14-0 against Jun 2007) was driven by suicidal-ideation and depression signals; FAERS still preserves the residual psychiatric cluster 18 years post-withdrawal. CANYON-1 Phase 1b summer 2026 readout will provide the first human CNS-AE evidence at obesity-relevant doses.

12. Optionality

12.1 Platform Beyond Lead

  • CRB-701 (Nectin-4 ADC) is the new lead oncology asset with clinical data in HNSCC and cervical cancer, and potential for broader Nectin-4-expressing tumors (breast, bladder, lung, etc.). Fast Track Designations and FDA alignment on registrational path provide a near-term regulatory readout. 994.
  • CRB-913 (CB1 inverse agonist) provides a metabolic disease opportunity (obesity) with mechanical differentiation from incretin analogs. CANYON-1 Phase 1b study will generate 12-week weight loss data in summer 2026; could open a large market adjacent to GLP-1 therapies. 135136.
  • CRB-601 (anti-αvβ8) is an early clinical-stage program targeting a novel PD-1/PD-L1-independent immunomodulatory pathway. If validated, could complement existing I-O combinations..

12.2 Repurposing Potential

  • Lenabasum (CB2 agonist) may still have utility in subsets of SSc or DM based on post-hoc analyses (mycophenolate background), but no active development announced. No new claims of repurposing.

12.3 Strategic Acquirer Logic

  • CRB-701 could be an attractive target for a large pharma with an existing Nectin-4 franchise (e.g., Seagen/Astellas' PADCEV partner) looking to expand into non-mUC indications or improve safety/efficacy. The Fast Track designations and clinical proof-of-concept in HNSCC/cervical increase attractiveness.
  • The CB1 inverse agonist space is underserved after rimonabant's withdrawal; CRB-913's favorable brain exposure profile and Phase 1b data could attract companies seeking an obesity asset complementary to incretins.

No acquirer information is verified; this logic is based solely on the asset profiles derived from verified claims.

13. Verdict

Corbus reads as a two-asset company with one asset carrying the weight. CRB-701 has produced a 47.6% ORR (10/21) in second-line HNSCC and 37.5% (6/16) in cervical at ESMO 2025, has FDA Fast Track in cervical (December 2024) and HNSCC (September 2025), and has a randomized registrational design aligned with the agency as of April 2026. None of that clinical data has been through peer review, both cohorts are single-arm and small, and the alpha-v beta-8 program at Pliant sits 18-24 months ahead with AACR 2026 numbers of its own. The balance sheet reads the same way from two directions: $163.3M at FY2025 close is roughly 22 months on mechanical burn, while management guides to 12+ months. Insider transactions were net negative into that setup -- C-suite plus Cormorant at -$344K in December 2025 -- and the CMO departs in June 2026. CRB-913's CANYON-1 12-week obesity readout arrives in summer 2026.

The deck says a nectin-4 ADC with Fast Track in two indications, an agency-aligned registrational design, and a second program reading out this summer; the record says 21- and 16-patient single-arm cohorts with no peer-reviewed CRB-701 data, a runway management itself guides to 12+ months, and a class competitor 18-24 months in front. This read is wrong if CRB-913 delivers placebo-adjusted weight reduction with no CNS or psychiatric treatment-emergent adverse events by the CANYON-1 12-week readout in summer 2026 and CRB-701's second-line HNSCC response rate is confirmed at or above 47.6% in randomized data by ASCO 2026.

§ Under the hood

How this read was built -- enough for a sceptic to check the machinery, and for a builder to judge the work. The sources behind every figure are gathered in the bibliography below.

What the machine did

Each read runs through an audit pipeline: agents query primary sources and transcribe the structured results. The model frames and orders the findings; it does not generate the underlying data. Every figure on the page traces to a source or is flagged as unverified.

Where a source is silent or a query returns nothing, the gap is flagged rather than filled. The read does not conduct interviews, enter private data rooms, model financial projections from assumptions, or run wet-lab experiments. A blank is honest; a confident guess is not.

Wired, and available but not called

The engine calls a focused set of primary sources directly:

  • SEC EDGAR -- XBRL financials, 8-K / S-1 filings, exhibit press releases
  • ClinicalTrials.gov -- trial registry: design, status, endpoints, results
  • PubMed / Europe PMC -- peer-reviewed literature, abstracts, full-text snippets
  • openFDA -- drug labels, Drugs@FDA approvals, FAERS adverse-event reports
  • USPTO / Google Patents -- patents, claims, assignment records
  • Stooq -- US equity daily close and volume
  • Web retrieval -- Jina Reader, Exa, Tavily for primary-document fetch and search

The engine is built on ToolUniverse (Harvard MIMS), the open library of more than 1,000 scientific tools -- structure and interaction databases (UniProt, RCSB PDB, AlphaFold, STRING), pathways and expression (Reactome, KEGG, GTEx, Open Targets), chemistry (ChEMBL, PubChem), oncology evidence (cBioPortal, OncoKB, CIViC), and more. These are available capability the engine reaches for only when a read needs them; a typical company read does not invoke them, so they are listed here as latent reach, not as work performed.

The custom code

  • Citation-URL builders -- turn every identifier (PMID, DOI, NCT, accession) into a canonical primary-source link -- the "two clicks from source" guarantee behind each figure.
  • Fact-audit pipeline -- grades each extracted claim by the tier of its source and assigns a verdict (verified, contradicted, unsupported, not-checkable) against the primary record.
  • Render and fact-token gates -- a schema gate and a fact-token invariant block a malformed report, and block any number, date, or trial id from drifting between the audit and the page.
  • Cross-family adversarial review -- two reviewers from other model families (DeepSeek R1, Kimi K2) independently challenge the primary analysis, so the read is not graded only by the model that wrote it.

§ References

  1. 1. Ajulemic acid (AJA, CT-3, IP-751, JBT-101, anabasum) is a first-in-class, synthetic, orally active, cannabinoid-derived drug that preferentially binds to the CB2 receptor and is nonpsychoactive. pubmed.ncbi.nlm.nih.gov. ^
  2. 2. otherNames: 1. lenabasum 2. anabasum 3. resunab 4. ajulemic acid 5. CT-3 6. IP751 7. CPL7075. clinicaltrials.gov. ^
  3. 3. Ajulemic acid (AJA, CT-3, IP-751, JBT-101, anabasum). pubmed.ncbi.nlm.nih.gov. ^
  4. 4. Lenabasum is a nonimmunosuppressive, nonpsychoactive cannabinoid receptor type 2 (CB2) agonist that promotes resolution of innate immune responses.unverified ^
  5. 5. CRB-913 is a novel cannabinoid receptor type 1 (CB1) inverse agonist (CB1-IA) that is being developed for once-daily treatment of obesity. clinicaltrials.gov. ^
  6. 6. Next-Generation CB1 Inverse Agonist. ir.corbuspharma.com. ^
  7. 7. Corbus Pharmaceuticals has a pipeline asset designated CRB-913, relevant to cannabinoid receptor 1 inverse agonism.unverified ^
  8. 8. Induction and maintenance regimens with CB1 inverse agonist CRB-913 and semaglutide in DIO mice. corbuspharma.com. ^
  9. 9. CRB-701 Next-Generation Nectin-4 Targeting ADC. d1io3yog0oux5.cloudfront.net. ^1 ^2
  10. 10. Lenabasum has anti-inflammatory effects, particularly on CD4+ T cells, T helper 1 cells, and myeloid cell lineages such as monocyte-derived dendritic cells.unverified ^
  11. 11. Lenabasum acts through the CB2 receptor, promoting the downregulation of proinflammatory cytokines.unverified ^
  12. 12. Binding of L-TGF-β to integrin αvβ8 results in activation of TGF-β. pubmed.ncbi.nlm.nih.gov. ^
  13. 13. It is expressed ubiquitously in a latent form that must be activated to function. pubmed.ncbi.nlm.nih.gov. ^
  14. 14. suggesting that tumor cell αvβ8 serves as a platform for activating cell-surface L-TGF-β presented by immune cells. pubmed.ncbi.nlm.nih.gov. ^
  15. 15. Inverse agonism of the cannabinoid receptor type 1 (CB1) is a clinically validated mechanism for promoting weight loss and improving related clinical outcomes.1. corbuspharma.com. ^
  16. 16. A new generation of peripherally restricted CB1 inverse agonists. corbuspharma.com. ^
  17. 17. It also demonstrated significant efficacy in preclinical models of inflammation and fibrosis. pubmed.ncbi.nlm.nih.gov. ^
  18. 18. It suppresses tissue scarring. pubmed.ncbi.nlm.nih.gov. ^
  19. 19. stimulates endogenous eicosanoids that resolve chronic inflammation and fibrosis. pubmed.ncbi.nlm.nih.gov. ^
  20. 20. resolve chronic inflammation and fibrosis without causing immunosuppression. pubmed.ncbi.nlm.nih.gov. ^
  21. 21. Inhibition of αvβ8 potentiates cytotoxic T cell responses. pubmed.ncbi.nlm.nih.gov. ^
  22. 22. Inhibition of αvβ8 potentiates cytotoxic T cell responses and recruitment of immune cells to tumor centers - effects that are independent of PD-1/PD-L1. pubmed.ncbi.nlm.nih.gov. ^1 ^2
  23. 23. Semaglutide Day 1-21; CRB-913 Day 22-41 -17.1. d1io3yog0oux5.cloudfront.net. ^1 ^2
  24. 24. Source: Morningstar et al-Obesity Week 2024. d1io3yog0oux5.cloudfront.net. ^
  25. 25. Despite similar peripheral exposure, CRB-913 demonstrated 15-fold lower brain exposure than monlunabant when measured by maximum concentration (Cmax), or area under the curve from 0 to 24 hours (AUC0-24) (Figure 5, Table 1). corbuspharma.com. ^1 ^2 ^3
  26. 26. groupId: OG001 value: -2.0 spread: 1.5. clinicaltrials.gov.contradicted ^
  27. 27. Median CRISS score at Visit 6 (Day 113) for combined lenabasum group was 0.330 (range 0.00-1.00), N=26. clinicaltrials.gov.unverified ^
  28. 28. New PEx were treated with intravenous antibiotics in 4.0% of lenabasum-treated vs. 11.4% of placebo-treated subjects, during Weeks 1-4. pubmed.ncbi.nlm.nih.gov. ^
  29. 29. groupId: OG000 value: -8.0 spread: 8.16. clinicaltrials.gov. ^
  30. 30. The overall test p-value comparing each active treatment vs. placebo at Day 29 using a 3 degree-of-freedom test (GEE, binomial distribution, logit link, Mixed Models Analysis) was 0.594, indicating no statistically significant difference.unverified ^
  31. 31. hasResults: False. clinicaltrials.gov. ^
  32. 32. In NCT03451045, the primary PEx rate over 28 weeks was 0.911 events per participant/28 weeks for Lenabasum 20 mg BID.unverified ^
  33. 33. In NCT03451045, the primary PEx rate over 28 weeks was 0.842 events per participant/28 weeks for Placebo BID.unverified ^
  34. 34. 1.8 mg/kg 2.7 mg/kg 3.6 mg/kg 4.5 mg/kg Completed. d1io3yog0oux5.cloudfront.net. ^
  35. 35. ORR 33.3% (4/12) 47.6% (10/21). d1io3yog0oux5.cloudfront.net. ^
  36. 36. DCR 75% 61.9%. d1io3yog0oux5.cloudfront.net. ^
  37. 37. CRB-701 at 3.6 mg/kg dose in HNSCC achieved ORR of 47.6% (10/21).unverified ^
  38. 38. CRB-701 at 3.6 mg/kg dose in HNSCC achieved DCR of 61.9%.unverified ^
  39. 39. ORR 22.2% (4/18) 37.5% (6/16). d1io3yog0oux5.cloudfront.net. ^
  40. 40. DCR 66.6% 68.8%. d1io3yog0oux5.cloudfront.net. ^
  41. 41. Efficacy (ORR) 37.5%. d1io3yog0oux5.cloudfront.net. ^
  42. 42. CRB-701 peripheral neuropathy rate was 8.4% (all grade 1 or 2), described as best-in-class.unverified ^1 ^2 ^3
  43. 43. CRB-701 skin adverse event rate was 28.7% (excluding alopecia) with low numbers of Grade ≥3 events (3/167).unverified ^1 ^2
  44. 44. Switching to CRB-913 from semaglutide at day 22 resulted in significantly greater additional weight loss than continuous semaglutide (weight loss from day 0 to day 41, 17.1% vs 13.6%, p < 0.01; Figure 3). corbuspharma.com. ^
  45. 45. enrollmentInfo: count: 252 type: ESTIMATED. clinicaltrials.gov. ^
  46. 46. CRB-913 Phase 1b study (CANYON-1) has been initiated with completion expected in summer 2026.unverified ^
  47. 47. The CANYON-1 Phase 1b study has a 1:1:1:1 randomization with N=240 subjects (60 per arm).unverified ^
  48. 48. Corbus Pharmaceuticals dosed the first patient in its first-in-human study of CRB-601 to treat patients with advanced solid tumors on 2024-12-09. ir.corbuspharma.com.unverified ^
  49. 49. patients with a history of psychiatric illness were more likely to discontinue rimonabant therapy early for all reasons, but most pronounced due to psychiatric events (rate ratio 1.79; 95% CI 1.54, 2.09) than those without a history of psychiatric illness. pubmed.ncbi.nlm.nih.gov. ^
  50. 50. focusing on psychiatric events, because these were the main safety concerns for rimonabant. pubmed.ncbi.nlm.nih.gov. ^
  51. 51. deathsNumAffected: 0 deathsNumAtRisk: 15. clinicaltrials.gov. ^
  52. 52. CRB-701 discontinuations due to eye toxicities have been low at 4.2%.unverified ^
  53. 53. The Phase 1a study of CRB-913 demonstrated a favorable safety profile. ir.corbuspharma.com.unverified ^
  54. 54. filer_position: Chief Medical Officer. sec.gov. ^1 ^2
  55. 55. filer_position: Chief Executive Officer. sec.gov. ^
  56. 56. Yuval Cohen, PhD Chief Executive Officer, Director. d1io3yog0oux5.cloudfront.net. ^
  57. 57. Corbus co-founder and Chief Executive Officer since 2014. d1io3yog0oux5.cloudfront.net. ^
  58. 58. Previously the President and co-founder of Celsus Therapeutics from 2005. d1io3yog0oux5.cloudfront.net. ^
  59. 59. filer_position: Chief Financial Officer. sec.gov. ^
  60. 60. Sean Moran, CPA, MBA Chief Financial Officer. d1io3yog0oux5.cloudfront.net. ^
  61. 61. Corbus co-founder and Chief Financial Officer since 2014. d1io3yog0oux5.cloudfront.net. ^
  62. 62. Prior senior financial management experience in emerging biotech and medical device companies. d1io3yog0oux5.cloudfront.net. ^
  63. 63. Dominic Smethurst, M.D., M.A., M.R.C.P. as Chief Medical Officer, effective June 30, 2026. sec.gov. ^
  64. 64. Dominic Smethurst Chief Medical Officer, MA MRCP. d1io3yog0oux5.cloudfront.net. ^
  65. 65. joined Corbus as our Chief Medical Officer in February 2024. d1io3yog0oux5.cloudfront.net. ^
  66. 66. He most recently served as CMO of Bicycle Therapeutics. d1io3yog0oux5.cloudfront.net. ^
  67. 67. filer_position: Chief Operating Officer. sec.gov. ^
  68. 68. Ian Hodgson, PhD Chief Operating Officer. d1io3yog0oux5.cloudfront.net. ^
  69. 69. Dr. Hodgson joined Corbus in 2022. Previously he held senior leadership positions in biotech and contract research organizations. d1io3yog0oux5.cloudfront.net. ^
  70. 70. Most recently served as V.P., Head of Clinical Services at TMC Pharma. d1io3yog0oux5.cloudfront.net. ^
  71. 71. Christina Bertsch, M.A. Head of Human Resources. d1io3yog0oux5.cloudfront.net. ^
  72. 72. Corbus Pharmaceuticals had cash, cash equivalents and investments of $163M as of December 31, 2025.unverified ^
  73. 73. $163M Cash, cash equivalents and investments as of December 31, 2025. d1io3yog0oux5.cloudfront.net. ^
  74. 74. Corbus Pharmaceuticals Announces Proposed Public Offering. ir.corbuspharma.com. ^
  75. 75. Corbus Pharmaceuticals Announces Pricing of Public Offering. ir.corbuspharma.com. ^1 ^2
  76. 76. shares: 6097.0, price_per_share: 8.2994, post_transaction_shares: 89790.0, value: 50601.4418, accession: 0001193125-26-091647, filing_date: 2026-03-04. sec.gov. ^
  77. 77. shares: 3285.0, price_per_share: 8.0898, post_transaction_shares: 95887.0, value: 26574.993000000002, accession: 0001193125-26-037647, filing_date: 2026-02-04. sec.gov. ^
  78. 78. shares: 847.0, price_per_share: 7.383, post_transaction_shares: 51080.0, value: 6253.401, accession: 0001193125-26-057174, filing_date: 2026-02-18. sec.gov. ^
  79. 79. shares: 2415.0, price_per_share: 8.0899, post_transaction_shares: 51927.0, value: 19537.1085, accession: 0001193125-26-037643, filing_date: 2026-02-04. sec.gov. ^
  80. 80. shares: 4701.0, price_per_share: 7.783, post_transaction_shares: 96694.0, value: 36587.883, accession: 0001193125-26-057168, filing_date: 2026-02-18. sec.gov. ^
  81. 81. shares: 13871.0, price_per_share: 7.7826, post_transaction_shares: 174316.0, value: 107952.4446, accession: 0001193125-26-057159, filing_date: 2026-02-18. sec.gov. ^
  82. 82. shares: 30029.0, price_per_share: 11.456, post_transaction_shares: 2344971.0, value: 344012.224, accession: 0000929638-25-004597, filing_date: 2025-12-15. sec.gov. ^
  83. 83. shares: 28365.0, price_per_share: 0.0, post_transaction_shares: 99172.0, accession: 0001193125-26-015429, filing_date: 2026-01-16. sec.gov. ^
  84. 84. shares: 85095.0, price_per_share: 8.26, post_transaction_shares: 99172.0, accession: 0001193125-26-015429, filing_date: 2026-01-16. sec.gov. ^
  85. 85. shares: 28082.0, price_per_share: 0.0, post_transaction_shares: 101395.0, accession: 0001193125-26-015427, filing_date: 2026-01-16. sec.gov. ^
  86. 86. shares: 84247.0, price_per_share: 8.26, post_transaction_shares: 101395.0, accession: 0001193125-26-015427, filing_date: 2026-01-16. sec.gov. ^
  87. 87. shares: 50000.0, price_per_share: 0.0, post_transaction_shares: 188187.0, accession: 0001193125-26-015426, filing_date: 2026-01-16. sec.gov. ^
  88. 88. shares: 150000.0, price_per_share: 8.26, post_transaction_shares: 188187.0, accession: 0001193125-26-015426, filing_date: 2026-01-16. sec.gov. ^
  89. 89. shares: 28365.0, price_per_share: 0.0, post_transaction_shares: 54342.0, accession: 0001193125-26-015430, filing_date: 2026-01-16. sec.gov. ^
  90. 90. shares: 85095.0, price_per_share: 8.26, post_transaction_shares: 54342.0, accession: 0001193125-26-015430, filing_date: 2026-01-16. sec.gov. ^
  91. 91. The FDA granted Fast Track Designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer on 2024-12-03. ir.corbuspharma.com.unverified ^
  92. 92. The FDA granted Fast Track Designation to CRB-701 for head and neck squamous cell carcinoma on 2025-09-16. ir.corbuspharma.com.unverified ^
  93. 93. CRB-701 has received FDA Fast Track Designation for HNSCC and Cervical cancer.unverified ^
  94. 94. FDA Fast Track Designation granted HNSCC and Cervical. d1io3yog0oux5.cloudfront.net. ^1 ^2
  95. 95. Corbus Pharmaceuticals announced broad alignment with FDA on a registration path for CRB-701 in second-line HNSCC and cervical cancer. ir.corbuspharma.com.unverified ^
  96. 96. date: 2026-04-07. ir.corbuspharma.com. ^
  97. 97. CRB-701 FDA update on registrational study protocol is anticipated in Q1 2026.unverified ^
  98. 98. CRB-701 Phase 1/2 monotherapy data readout is anticipated mid-2026.unverified ^
  99. 99. CRB-701 combination data with Keytruda (pembrolizumab) in 1L setting is anticipated in Q4 2026.unverified ^
  100. 100. Total incident HNSCC U.S. patient population in 2025 is approximately 73,000.unverified ^
  101. 101. Approximately 50,000 HNSCC patients are locally advanced or metastatic in the U.S. in 2025, representing approximately 68% of total incident patients.unverified ^
  102. 102. Approximately 24,000 HNSCC patients progress to 2L+ in the U.S. in 2025, representing approximately 60% of 1L-treated patients.unverified ^
  103. 103. 73 K Total Incident HNSCC. d1io3yog0oux5.cloudfront.net. ^
  104. 104. ~68% locally adv / metastatic 50 K Locally Adv / Metastatic. d1io3yog0oux5.cloudfront.net. ^
  105. 105. ~60% progress to 2L+ 24 K. d1io3yog0oux5.cloudfront.net. ^
  106. 106. 14,0001 • Annual new cases in U.S. • 4,000 annual deaths. d1io3yog0oux5.cloudfront.net. ^
  107. 107. $1.8bn4 • U.S. market for cervical cancer treatment. d1io3yog0oux5.cloudfront.net. ^
  108. 108. 14 K Total Incident CC. d1io3yog0oux5.cloudfront.net. ^
  109. 109. 88% Localized. d1io3yog0oux5.cloudfront.net. ^
  110. 110. 70% Regional. d1io3yog0oux5.cloudfront.net. ^
  111. 111. 39% Distant. d1io3yog0oux5.cloudfront.net. ^
  112. 112. Source: SEER Bladder Cancer; Census.gov; Weir et al., 2021; American Cancer Society; Chu et al., 2022; Hoffman-Censits et al., 2022. SEER Cervical Cancer; Census.gov; Weir et al., 2021; American Cancer Society; Mizuho Analyst Report; Corbus Corporate Deck. SEER Oral Cavity & Pharynx Cancer; SEER Laryngeal Cancer; American Cancer Society; Sanders et al., 2022. LifeSci Consulting Qualitative Market Research. d1io3yog0oux5.cloudfront.net. ^
  113. 113. HNSCC 5-year survival is 86% for localized, 66% for regional, and 37% for distant disease.unverified ^
  114. 114. Cervical cancer 5-year survival is 88% for localized, 70% for regional, and 39% for distant disease.unverified ^
  115. 115. 86% Localized. d1io3yog0oux5.cloudfront.net. ^
  116. 116. Current 1L treatment for HNSCC includes Keytruda plus Platinum plus Paclitaxel and Keytruda plus Platinum plus 5-FU.unverified ^
  117. 117. Current 2L treatment for HNSCC includes single-agent or combo chemotherapy.unverified ^
  118. 118. Current 1L treatment for cervical cancer includes Carbo + Paclitaxel + Beva +/- Keytruda.unverified ^
  119. 119. Current 2L treatment for cervical cancer includes Tivdak and single-agent chemotherapy.unverified ^
  120. 120. Efficacy (ORR) 36%. d1io3yog0oux5.cloudfront.net. ^
  121. 121. Efficacy (ORR) 23.9%. d1io3yog0oux5.cloudfront.net. ^
  122. 122. Dosing regimen 1.25mg/kg on d1/8/15 of 28-day. d1io3yog0oux5.cloudfront.net. ^
  123. 123. Dosing regimen 1500mg Q2W. d1io3yog0oux5.cloudfront.net. ^
  124. 124. Padcev sales reached approximately USD 1.59 billion in 2024 (full-year). sec.gov. ^
  125. 125. Comparator Monlunabant Phase 2a study enrolled 240 subjects with obesity in Canada with dose cohorts of placebo, 10, 20 and 50 mg QD, no titration, and did not exclude PHQ-9 > 4 at baseline.unverified ^
  126. 126. Discontinuations 20.6% (78/379). d1io3yog0oux5.cloudfront.net.unverified ^1 ^2
  127. 127. Dose interruptions 55.9% (n=212/379) 53% (n=24/45). d1io3yog0oux5.cloudfront.net.unverified ^1 ^2
  128. 128. CRB-701 has markedly reduced PADCEV-associated toxicities compared to PADCEV.unverified ^
  129. 129. CRB-701 has a lower DAR and longer half-life enabling higher and longer dosing than PADCEV.unverified ^
  130. 130. CRB-701 has a precise and stable DAR of 2, resulting in a longer half-life.unverified ^
  131. 131. CRB-701 has improved linker stability resulting in reduced free MMAE.unverified ^
  132. 132. CRB-701 has a key differentiator of lower levels of free MMAE compared to PADCEV®.unverified ^
  133. 133. In NCT03451045, for Gastrointestinal disorders, EG000 (n=165 at risk) had 70 events affecting 57 participants.unverified ^
  134. 134. Semaglutide Day 1-21; Vehicle Day 22-41 -13.7 2.1. d1io3yog0oux5.cloudfront.net.contradicted ^
  135. 135. Highly Peripherally-Restricted CB1 receptor inverse agonist. d1io3yog0oux5.cloudfront.net. ^
  136. 136. CRB-913 12-week dose-range finding data in patients with obesity (n=240) in summer 2026. d1io3yog0oux5.cloudfront.net. ^